Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$3.15 – $5.00
0% from low
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $23.16B | $24.78B | $30.09B | $51.08B | $34.34B | $42.87B | $33.07B | $40.57B |
| Cost of revenue | $6.57B | $7.90B | $7.81B | $10.46B | $8.89B | $11.62B | $11.33B | $10.32B |
| Gross profit | $16.59B | $16.88B | $22.27B | $40.62B | $25.46B | $31.25B | $21.74B | $30.25B |
| Gross margin | 71.6% | 68.1% | 74.0% | 79.5% | 74.1% | 72.9% | 65.7% | 74.6% |
| R&D | $4.35B | $6.00B | $5.36B | $7.17B | $8.80B | $11.23B | $102.9M | $16.87B |
| Operating income | $4.97B | $3.24B | $8.27B | $19.93B | $4.97B | $7.53B | −$6.65B | $433.7M |
| EBITDA | $6.31B | $4.68B | $10.59B | $21.39B | $7.45B | $10.53B | −$2.88B | $3.01B |
| Net income | $3.71B | $2.68B | $6.89B | $14.51B | $3.77B | $5.51B | −$4.76B | $2.19B |
| Net margin | 16.0% | 10.8% | 22.9% | 28.4% | 11.0% | 12.8% | -14.4% | 5.4% |
| EPS (diluted) | 29.99 | 21.59 | 55.52 | 116.79 | 30.22 | 43.92 | -38.43 | 17.58 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2027 | $45.7B | $3.27 | $2.47–$3.60 | 1 |
| 2028 | $42.0B | $3.19 | $2.41–$3.51 | 1 |
| 2029 | $43.0B | $11.14 | $8.41–$12.26 | 1 |
| 2030 | $45.9B | $19.57 | $14.77–$21.55 | 1 |
Forward consensus · source: Financial Modeling Prep
JCR PHARMACEUTICALS CO
No one on the platform currently holds JCRRF.
No tracked institution reports a position in JCRRF as of their last filing.
| Ex-date | Per share | Pay date |
|---|---|---|
| 2027-03-31 | $10.0000 | |
| 2026-09-30 | $10.0000 | |
| 2026-03-31 | $10.0000 | 2026-06-24 |
| 2025-09-30 | $10.0000 | 2025-12-05 |
| 2025-03-31 | $10.0000 | 2025-06-26 |
| 2024-09-30 | $10.0000 | 2024-12-06 |
| 2024-03-28 | $10.0000 | 2024-06-27 |
| 2023-09-29 | $10.0000 | 2023-12-08 |
No one on the platform has traded JCRRF yet.
| +6.33% |
| $554M |
| — |
| GLASFGlass House Brands Inc. | $12.34 | +1.06% | $974M | — |
| GSGTFGenSight Biologics S.A. | $0.09 | +0.00% | $15M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.